Royalty Pharma (RPRX) expects 2025 Portfolio Receipts to be between $3,200 million and $3,250 million, previously $3,050 million to $3,150 million, representing expected growth of 14% to 16%.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPRX:
- Royalty Pharma acquires royalty interest in Alnylam’s AMVUTTRA for $310M
- Royalty Pharma price target lowered to $54 from $55 at Morgan Stanley
- Royalty Pharma: Strategic Positioning and Growth Potential Drive Buy Rating
- Royalty Pharma initiated with a Buy at Goldman Sachs
- Royalty Pharma appoints Ted Love as lead independent director